CNS Pharmaceuticals Inc. Common Stock (CNSP)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, endure, and sell for less than they are worth. CNS Pharmaceuticals does not fit that mold. It is an eight-employee clinical-stage biotechnology firm with no revenue in any period shown, developing TPI 287 and Berubicin for neurology and oncology. The filed figures show a net loss of $18.9M in fiscal year 2023, the year ended 2023-12-31; $14.9M in fiscal year 2024, the year ended 2024-12-31; and $15.9M in fiscal year 2025, the year ended 2025-12-31. It then lost $4.9M in fiscal Q1 2026, the quarter ended 2026-03-31, and $2.6M in fiscal Q2 2026, the quarter ended 2026-06-30. That is not a business compounding value; it is a cash-consuming research effort. As of the 2026-10-13 close, FairStock calculations show a $2.0M market cap, P/B of 0.43, P/E of -0.35, ROE of -106.62%, ROCE of -58.01%, trailing free cash flow of -$13.4M, FCF yield of -685.9%, Piotroski F-Score of 1/9, and Altman Z-Score of -5.57. The P/B might tempt a Graham-style asset buyer, but with no revenue and heavy cash burn, book value is unlikely to provide a durable margin of safety. Debt is low, with D/E of 0.07, but equity is being consumed. A true moat would require approved products, pricing power, and recurring cash flows; none are evident here. The stock is a speculative bet on clinical trial outcomes, not a value investment. At $5.35 on 2026-10-13, the price may look statistically cheap, but the underlying business remains fragile.

In plain English: CNS Pharmaceuticals is a small clinical-stage drug developer with no product sales, testing experimental treatments for brain and other cancers. The business looks weak: it keeps losing money and burning cash, with no profits in the periods shown. The shares trade below the value of its assets on the books, but because there are no earnings and losses are heavy, the price looks speculative rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer